|
Baseline Demographic and Clinical Data |
|||
| Treatment |
Placebo |
P value |
|
|
|
|||
| n (female/male) |
35 (22/13) |
40 (28/12) |
0.513 |
| Age (yr) |
44.5 ± 2.2 |
45.3 ± 2.0 |
0.796 |
| Blood pressure (systolic/diastolic, mmHg) |
121/69 ± 2.2/1.4 |
121.6/67.1 ± 1.9/1.5 |
0.868/0.760 |
| Weight (kg) |
81.8 ± 2.8 |
79.6 ± 2.9 |
0.598 |
| Total Cholesterol (mmol/L) |
6.2 ± 0.1 |
6.2 ± 0.1 |
0.976 |
| Triglyceride (mmol/L)* |
1.9 ± 0.1 |
1.9 ± 0.2 |
0.989 |
| HDL cholesterol (mmol/L) |
1.4 ± 0.06 |
1.3 ± 0.05 |
0.806 |
| LDL cholesterol (mmol/L)** |
4.1 ± 0.1 |
4.2 ± 0.1 |
0.651 |
| Cholesterol/HDL ratio |
4.8 ± 0.2 |
4.8 ± 0.2 |
0.981 |
| C-Reactive protein (mg/dL) |
0.35 ± 0.08 |
0.38 ± .06 |
0.817 |
| Homocysteine (μmol/L) |
8.0 ± 0.3 |
7.9 ± 0.3 |
0.861 |
| Insulin (pmol/L) |
56.2 ± 4.2 |
68.1 ± 9.0 |
0.273 |
| Glucose (mmol/L) |
5.4 ± 0.3 |
5.3 ± 0.1 |
0.840 |
|
Data are means ± SEM. * Excludes one subject in the Placebo group with fasting triglycerides > 400 mg/dL. ** Excludes two subjects in the Placebo group with fasting triglycerides > 400 mg/dL | |||
Queenan et al. Nutrition Journal 2007 6:6 doi:10.1186/1475-2891-6-6 |
|||